Cargando…
Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ)
OBJECTIVE: To develop and validate a new scale to assess treatment burden (the effort of looking after one’s health) for patients with multimorbidity. DESIGN: Mixed-methods. SETTING: UK primary care. PARTICIPANTS: Content of the Multimorbidity Treatment Burden Questionnaire (MTBQ) was based on a lit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900423/ https://www.ncbi.nlm.nih.gov/pubmed/29654011 http://dx.doi.org/10.1136/bmjopen-2017-019413 |
_version_ | 1783314410160259072 |
---|---|
author | Duncan, Polly Murphy, Mairead Man, Mei-See Chaplin, Katherine Gaunt, Daisy Salisbury, Chris |
author_facet | Duncan, Polly Murphy, Mairead Man, Mei-See Chaplin, Katherine Gaunt, Daisy Salisbury, Chris |
author_sort | Duncan, Polly |
collection | PubMed |
description | OBJECTIVE: To develop and validate a new scale to assess treatment burden (the effort of looking after one’s health) for patients with multimorbidity. DESIGN: Mixed-methods. SETTING: UK primary care. PARTICIPANTS: Content of the Multimorbidity Treatment Burden Questionnaire (MTBQ) was based on a literature review and views from a patient and public involvement group. Face validity was assessed through cognitive interviews. The scale was piloted and the final version was tested in 1546 adults with multimorbidity (mean age 71 years) who took part in the 3D Study, a cluster randomised controlled trial. For each question, we examined the proportion of missing data and the distribution of responses. Factor analysis, Cronbach’s alpha, Spearman’s rank correlations and longitudinal regression assessed dimensional structure, internal consistency reliability, construct validity and responsiveness, respectively. We assessed interpretability by grouping the global MTBQ scores into zero and tertiles (>0) and comparing participant characteristics across these categories. RESULTS: Cognitive interviews found good acceptability and content validity. Factor analysis supported a one-factor solution. Cronbach’s alpha was 0.83, indicating internal consistency reliability. The MTBQ score had a positive association with a comparator treatment burden scale (r(s) 0.58, P<0.0001) and with self-reported disease burden (r(s) 0.43, P<0.0001), and a negative association with quality of life (r(s)−0.36, P<0.0001) and self-rated health (r(s)−0.36, P<0.0001). Female participants, younger participants and participants with mental health conditions were more likely to have high treatment burden scores. Changes in MTBQ score over 9-month follow-up were associated, as expected, with changes in measures of quality of life (EuroQol five dimensions, five level questionnaire) and patient-centred care (Patient Assessment of Chronic Illness Care). CONCLUSION: The MTBQ is a 10-item measure of treatment burden for patients with multimorbidity that has demonstrated good content validity, construct validity, reliability and responsiveness. It is a useful research tool for assessing the impact of interventions on treatment burden. TRIAL REGISTRATION NUMBER: ISRCTN06180958. |
format | Online Article Text |
id | pubmed-5900423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-59004232018-04-17 Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) Duncan, Polly Murphy, Mairead Man, Mei-See Chaplin, Katherine Gaunt, Daisy Salisbury, Chris BMJ Open General practice / Family practice OBJECTIVE: To develop and validate a new scale to assess treatment burden (the effort of looking after one’s health) for patients with multimorbidity. DESIGN: Mixed-methods. SETTING: UK primary care. PARTICIPANTS: Content of the Multimorbidity Treatment Burden Questionnaire (MTBQ) was based on a literature review and views from a patient and public involvement group. Face validity was assessed through cognitive interviews. The scale was piloted and the final version was tested in 1546 adults with multimorbidity (mean age 71 years) who took part in the 3D Study, a cluster randomised controlled trial. For each question, we examined the proportion of missing data and the distribution of responses. Factor analysis, Cronbach’s alpha, Spearman’s rank correlations and longitudinal regression assessed dimensional structure, internal consistency reliability, construct validity and responsiveness, respectively. We assessed interpretability by grouping the global MTBQ scores into zero and tertiles (>0) and comparing participant characteristics across these categories. RESULTS: Cognitive interviews found good acceptability and content validity. Factor analysis supported a one-factor solution. Cronbach’s alpha was 0.83, indicating internal consistency reliability. The MTBQ score had a positive association with a comparator treatment burden scale (r(s) 0.58, P<0.0001) and with self-reported disease burden (r(s) 0.43, P<0.0001), and a negative association with quality of life (r(s)−0.36, P<0.0001) and self-rated health (r(s)−0.36, P<0.0001). Female participants, younger participants and participants with mental health conditions were more likely to have high treatment burden scores. Changes in MTBQ score over 9-month follow-up were associated, as expected, with changes in measures of quality of life (EuroQol five dimensions, five level questionnaire) and patient-centred care (Patient Assessment of Chronic Illness Care). CONCLUSION: The MTBQ is a 10-item measure of treatment burden for patients with multimorbidity that has demonstrated good content validity, construct validity, reliability and responsiveness. It is a useful research tool for assessing the impact of interventions on treatment burden. TRIAL REGISTRATION NUMBER: ISRCTN06180958. BMJ Publishing Group 2018-04-12 /pmc/articles/PMC5900423/ /pubmed/29654011 http://dx.doi.org/10.1136/bmjopen-2017-019413 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | General practice / Family practice Duncan, Polly Murphy, Mairead Man, Mei-See Chaplin, Katherine Gaunt, Daisy Salisbury, Chris Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) |
title | Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) |
title_full | Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) |
title_fullStr | Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) |
title_full_unstemmed | Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) |
title_short | Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) |
title_sort | development and validation of the multimorbidity treatment burden questionnaire (mtbq) |
topic | General practice / Family practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900423/ https://www.ncbi.nlm.nih.gov/pubmed/29654011 http://dx.doi.org/10.1136/bmjopen-2017-019413 |
work_keys_str_mv | AT duncanpolly developmentandvalidationofthemultimorbiditytreatmentburdenquestionnairemtbq AT murphymairead developmentandvalidationofthemultimorbiditytreatmentburdenquestionnairemtbq AT manmeisee developmentandvalidationofthemultimorbiditytreatmentburdenquestionnairemtbq AT chaplinkatherine developmentandvalidationofthemultimorbiditytreatmentburdenquestionnairemtbq AT gauntdaisy developmentandvalidationofthemultimorbiditytreatmentburdenquestionnairemtbq AT salisburychris developmentandvalidationofthemultimorbiditytreatmentburdenquestionnairemtbq |